Lamotrigine and its N2-glucuronide during pregnancy: The significance of renal clearance and estradiol

Epilepsy Research

Volumn 94, Issue 3, 2011, Pages 198-205

  Reimers, Arne ^a,b   Helde, Grethe ^b   Bråthen, Geir ^a,b   Brodtkorb, Eylert ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Estradiol; Glucuronide; Lamotrigine; Pregnancy; Renal clearance; UGT1A4

Indexed keywords

DRUG METABOLITE; ESTRADIOL; LAMOTRIGINE; LAMOTRIGINE N2 GLUCURONIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG URINE LEVEL; EPILEPSY; ESTRADIOL BLOOD LEVEL; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; ANTICONVULSANTS; EPILEPSY; ESTRADIOL; FEMALE; HUMANS; OUTPATIENTS; POSTPARTUM PERIOD; PREGNANCY; PROSPECTIVE STUDIES; RENAL CIRCULATION; TRIAZINES; YOUNG ADULT;

EID: 79955524916     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.02.002     Document Type: Article

References (43)

1. Anderson G.D. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet. 2005, 44:989-1008.
2. Bock K.W. Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels. Biochem. Pharmacol. 2010, 80:771-777.
3. Beck O., Ohman I., Nordgren H.K. Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry. Ther. Drug Monit. 2006, 28:603-607.
4. Brodtkorb E., Reimers A. Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy. Seizure 2008, 17:160-165.
5. Chan V., Morris R.G., Ilett K.F., Tett S.E. Population pharmacokinetics of lamotrigine. Ther. Drug. Monit. 2001, 23:630-635.
6. Chen S., Beaton D., Nguyen N., Senekeo-Effenberger K., Brace-Sinnokrak E., Argikar U., Remmel R.P., Trottier J., Barbier O., Ritter J.K., Tukey R.H. Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J. Biol. Chem. 2005, 280:37547-37557.
7. Chen H., Yang K., Choi S., Fischer J.H., Jeong H. Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab. Dispos. 2009, 37:1841-1847.
8. Cohen A.F., Land G.S., Breimer D.D., Yuen W.C., Winton C., Peck A.W. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther. 1987, 42:535-541.
9. Davison J.M. Kidney function in pregnant women. Am. J. Kidney Dis. 1987, 9:248-252.
10. de Haan G.J., Edelbroek P., Segers J., Engelsman M., Lindhout D., Devile-Notschaele M., Augustijn P. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004, 63:571-573.
11. Dickens M., Chen C. Lamotrigine. Chemistry, biotransformation and pharmacokinetics. Antiepileptic Drugs 2002, 370-379. Lippincott Williams & Wilkins, Philadelphia. R.H. Levy, R. Mattson, B. Meldrum, E. Perucca (Eds.).
12. Doig M.V., Clare R.A. Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, Lamotrigine. J. Chromatogr. 1991, 554:181-189.
13. Fotopoulou C., Kretz R., Bauer S., Schefold J.C., Schmitz B., Dudenhausen J.W., Henrich W. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res. 2009, 85:60-64.
14. Garnett W.R. Lamotrigine: pharmacokinetics. J. Child Neurol. 1997, 12(Suppl. 1):S10-15.
15. Harden C.L., Herzog A.G., Nikolov B.G., Koppel B.S., Christos P.J., Fowler K., Labar D.R., Hauser W.A. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 2006, 47:1447-1451.
16. Jamjute P., Ahmad A., Ghosh T., Banfield P. Liver function test and pregnancy. J. Matern. Fetal Neonatal Med. 2009, 22:274-283.
17. Klajnbard A., Szecsi P.B., Colov N.P., Andersen M.R., Jorgensen M., Bjorngaard B., Barfoed A., Haahr K., Stender S. Laboratory reference intervals during pregnancy, delivery and the early postpartum period. Clin. Chem. Lab Med. 2010, 48:237-248.
18. Kristensen K., Lindstrom V., Schmidt C., Blirup-Jensen S., Grubb A., Wide-Swensson D., Strevens H. Temporal changes of the plasma levels of cystatin C, beta-trace protein, beta2-microglobulin, urate and creatinine during pregnancy indicate continuous alterations in the renal filtration process. Scand. J. Clin. Lab Invest. 2007, 67:612-618.
19. McAnulty J.H., Broberg C.S., Metcalfe J. Chapter 96. Heart disease and pregnancy. Hurst's the Heart 2008, McGraw-Hill Medical Publishing Division. V. Fuster, R.A. O'Rourke, R.A. Walsh, P.-W. Philip (Eds.).
20. Milovanovic J.R., Jankovic S.M. Population pharmacokinetics of lamotrigine in patients with epilepsy. Int. J. Clin. Pharmacol. Ther. 2009, 47:752-760.
21. Ohman I., Vitols S., Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000, 41:709-713.
22. Ohman I., Beck O., Vitols S., Tomson T. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia 2008, 49:1075-1080.
23. Pavek P., Ceckova M., Staud F. Variation of drug kinetics in pregnancy. Curr. Drug Metab. 2009, 10:520-529.
24. Pennell P.B. 2005 AES annual course: evidence used to treat women with epilepsy. Epilepsia 2006, 47(Suppl. 1):46-53.
25. Pennell P.B., Newport D.J., Stowe Z.N., Helmers S.L., Montgomery J.Q., Henry T.R. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004, 62:292-295.
26. Pennell P.B., Peng L., Newport D.J., Ritchie J.C., Koganti A., Holley D.K., Newman M., Stowe Z.N. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008, 70:2130-2136.
27. Petrenaite V., Sabers A., Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res. 2005, 65:185-188.
28. Reimers A. Trends and changes in the clinical use of lamotrigine. Pharmacoepidemiol. Drug Saf. 2009, 18:132-139.
29. Reimers A., Helde G., Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005, 46:1414-1417.
30. Reimers A., Skogvoll E., Sund J.K., Spigset O. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J. Clin. Psychopharmacol. 2005, 25:342-348.
31. Reimers A., Brodtkorb E., Helde G., Spigset O. Lamotrigine serum concentrations throughout the menstrual cycle-a study of 2 cases. Clin. Neuropharmacol. 2006, 29:160-162.
32. Sabers A., Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine monotherapy. Epilepsia 2009, 50:2163-2166.
33. Sabers A., Tomson T. Managing antiepileptic drugs during pregnancy and lactation. Curr. Opin. Neurol. 2009, 22:157-161.
34. Sabers A., Öhman I., Christensen J., Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003, 61:570-571.
35. Sabers A., Dam M.A., Rogvi-Hansen B., Boas J., Sidenius P., Laue Friis M., Alving J., Dahl M., Ankerhus J., Mouritzen Dam A. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol. Scand. 2004, 109:9-13.
36. Shenfield G.M. Oral contraceptives. Are drug interactions of clinical significance?. Drug Saf. 1993, 9:21-37.
37. Sturgiss S.N., Dunlop W., Davison J.M. Renal haemodynamics and tubular function in human pregnancy. Baillieres Clin. Obstet. Gynaecol. 1994, 8:209-234.
38. Tomson T., Ohman I., Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997, 38:1039-1041.
39. Tran T.A., Leppik I.E., Blesi K., Sathanandan S.T., Remmel R. Lamotrigine clearance during pregnancy. Neurology 2002, 59:251-255.
40. Viguera A.C., Cohen L.S., Baldessarini R.J., Nonacs R. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can. J. Psychiatry 2002, 47:426-436.
41. Wegner I., Edelbroek P.M., Bulk S., Lindhout D. Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. Neurology 2009, 73:1388-1393.
42. Wootton R., Soul-Lawton J., Rolan P.E., Sheung C.T., Cooper J.D., Posner J. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br. J. Clin. Pharmacol. 1997, 43:23-27.
43. Yonkers K.A., Wisner K.L., Stowe Z., Leibenluft E., Cohen L., Miller L., Manber R., Viguera A., Suppes T., Altshuler L. Management of bipolar disorder during pregnancy and the postpartum period. Am. J. Psychiatry 2004, 161:608-620.